DTC spend lagged in '08, says TNS

Share this article:
Spending on DTC launch campaigns dropped this year as companies waited longer to market fewer new drugs with more limited indications, said a TNS Media Intelligence report. 

The market research firm found that spending on launch campaigns accounted for a tenth of overall DTC ad spend for the first eight months of 2008 – down from the 13%-15% typical in years past. That drop was a major driver in slowing DTC spend, down 6.3% for the first eight months over the same period in 2007 to $3.3 billion. 
It's the second consecutive drop in DTC spending, which was down 3.1% for the same period last year. 

TNS said prescription drug advertising, which accounts for over 90% of DTC spending, slipped 3.6% for the first eight months, reversing a 3.5% gain for the same period last year. 

But the drop in launch spending, with aggregate spending down $155 million for the first eight months, may be more momentous, said TNS. “Launch introductions are a bellwether indicator,” the report's authors wrote. “Marginal swings in introductory spending, up or down, can move the needle for the entire Rx category and represent the difference between category growth and decline.”

Companies are skimping on spending for launches, presumably as marketers take their share of across-the-board cost-cutting exercises. But companies are also waiting longer to market new drugs to consumers, in accordance with PhRMA guidelines on DTC and in response to pressure from regulators. And an increasing share of launches are for narrow new indications, not new drugs, making for more targeted campaigns. 

TNS also found TV spend on the upswing. Spending on TV accounted for 63% of all DTC spend for the period—up from 59% for all of 2007. Meanwhile, magazine advertising was down 19.5% for the year to date.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.